Bionano Story

Your bind date with Bionano Genomics
The successful prediction of Bionano Genomics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Bionano Genomics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Bionano Genomics based on Bionano Genomics hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Bionano Genomics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Bionano Genomics's related companies.

Use Technical Analysis to project Bionano expected Price

Bionano Genomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.

Overlap Analysis View

Forecast Models View

Price Shifting View

Volatility Indicators View

Value Movement View

A focus of Bionano Genomics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Bionano Genomics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Bionano utilizes its cash?

To perform a cash flow analysis of Bionano Genomics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bionano Genomics is receiving and how much cash it distributes out in a given period. The Bionano Genomics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Bionano Genomics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (28.67 Million)

Acquisition by Chaubey Alka of 300000 shares of Bionano Genomics subject to Rule 16b-3

Legal trades by Bionano Genomics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Bionano insider trading alert for grant of stock option (right to buy) by Chaubey Alka, Chief Medical Officer, on 11th of October 2020. This event was filed by Bionano Genomics Inc with SEC on 2020-09-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Bionano Genomics Indicators

About Contributor